Evolus announced it expects the European Medicines Agency, or EMA, Committee for Medicinal Products for Human Use, or CHMP, to adopt a formal opinion on the Nuceiva marketing authorization application, or MAA, during the April committee meeting. Nuceiva is being evaluated by the EMA for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown, when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.